|
HK1225742A1
(zh)
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma, Inc. |
TGF-β受体II型变体及其用途
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
HRP20210977T1
(hr)
|
2014-02-10 |
2021-09-17 |
Merck Patent Gmbh |
Ciljano inhibiranje tgf beta
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
US11219694B2
(en)
|
2015-09-24 |
2022-01-11 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for reducing metastases
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
CA3024465A1
(en)
*
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
JP7573365B2
(ja)
*
|
2016-08-12 |
2024-10-25 |
メルク パテント ゲーエムベーハー |
癌の併用療法
|
|
KR102617453B1
(ko)
|
2016-09-19 |
2023-12-26 |
현대모비스 주식회사 |
보조 표지판 인식 장치 및 그 방법
|
|
US10906957B2
(en)
|
2016-09-27 |
2021-02-02 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
IL307242B1
(en)
|
2016-12-07 |
2026-07-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
EP3565839A4
(en)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
CHECKPOINT REGULATOR ANTAGONISTS
|
|
CN110198738A
(zh)
*
|
2017-01-07 |
2019-09-03 |
默克专利有限公司 |
用于靶向的TGF-β抑制的给药方案和剂型
|
|
CA3049652A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
GB201700567D0
(en)
*
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
IL268995B2
(en)
|
2017-03-02 |
2024-02-01 |
Nat Res Council Canada |
TGF-B receptor ectodomain fusion compounds and their uses
|
|
SG11201909064RA
(en)
*
|
2017-03-30 |
2019-10-30 |
Merck Patent Gmbh |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
EP3612563A1
(en)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
LT3628049T
(lt)
|
2017-05-04 |
2023-08-25 |
Acceleron Pharma Inc. |
Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
|
|
AU2018266103B2
(en)
|
2017-05-09 |
2024-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
|
|
CN110050000B
(zh)
*
|
2017-05-12 |
2022-07-26 |
苏州盛迪亚生物医药有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
WO2019046856A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
|
|
KR102757384B1
(ko)
|
2017-09-27 |
2025-01-20 |
에피센트알엑스, 인코포레이티드 |
면역조절 융합 단백질
|
|
WO2019090263A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
JP7348899B2
(ja)
*
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN119431579A
(zh)
|
2018-03-09 |
2025-02-14 |
艾吉纳斯公司 |
抗cd73抗体及其使用方法
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765019A1
(en)
|
2018-03-14 |
2021-01-20 |
Merck Patent GmbH |
Compounds and uses thereof to treat tumors in a subject
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
EP3788067A4
(en)
|
2018-05-03 |
2022-01-19 |
Acceleron Pharma Inc. |
NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
|
|
AU2019262139A1
(en)
*
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
|
BR112020022145A2
(pt)
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
|
BR112020021082A2
(pt)
*
|
2018-05-15 |
2021-02-17 |
Merck Patent Gmbh |
regimes de dosagem para inibição de tgf-b direcionada para uso no tratamento de câncer em indivíduos sem tratamento prévio
|
|
US20210154316A1
(en)
|
2018-05-17 |
2021-05-27 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
CA3103245A1
(en)
*
|
2018-06-13 |
2019-12-19 |
Merck Patent Gmbh |
Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
|
|
EP3808376A4
(en)
|
2018-06-17 |
2021-09-01 |
L&L Biopharma Co., Ltd. |
CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
|
|
JP2021528399A
(ja)
*
|
2018-06-22 |
2021-10-21 |
メルク パテント ゲーエムベーハー |
胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
|
|
JP2021529557A
(ja)
|
2018-06-29 |
2021-11-04 |
ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． |
抗腫瘍免疫チェックポイント調節因子アンタゴニスト
|
|
JP2021529777A
(ja)
*
|
2018-07-02 |
2021-11-04 |
メルク パテント ゲーエムベーハー |
進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CN112672753B
(zh)
*
|
2018-07-09 |
2025-07-08 |
普瑞赛格恩公司 |
融合构建体及其使用方法
|
|
CN113271962A
(zh)
*
|
2018-08-22 |
2021-08-17 |
默克专利有限公司 |
利用靶向TGF-β抑制的三阴性乳腺癌的治疗
|
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
|
|
CA3117429A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Patent Gmbh |
Anti-tim-3 antibodies
|
|
AU2019372436A1
(en)
*
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
CA3118415A1
(en)
|
2018-11-09 |
2020-05-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof
|
|
SG11202105975SA
(en)
*
|
2018-12-06 |
2021-07-29 |
Guangdong Tcrcure Biopharma Technology Co Ltd |
Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
|
KR102815892B1
(ko)
*
|
2019-06-10 |
2025-06-04 |
샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 |
PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도
|
|
JP2022537158A
(ja)
|
2019-06-13 |
2022-08-24 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
|
|
CN110218260A
(zh)
*
|
2019-06-24 |
2019-09-10 |
王跃驹 |
植物作为宿主在表达m7842中的应用
|
|
EP3990116A1
(en)
*
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN112239507A
(zh)
*
|
2019-07-17 |
2021-01-19 |
鸿运华宁（杭州）生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
|
|
AU2020328050B2
(en)
*
|
2019-08-15 |
2023-09-07 |
Nantbio, Inc. |
TGF-beta trap
|
|
CN114072428B
(zh)
*
|
2019-08-30 |
2024-02-13 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
|
US20220313835A1
(en)
|
2019-09-03 |
2022-10-06 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
WO2021046347A1
(en)
|
2019-09-04 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CN112442132A
(zh)
*
|
2019-09-05 |
2021-03-05 |
复旦大学 |
靶向肿瘤的重组双功能融合蛋白及其应用
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
EP4038053A1
(en)
|
2019-09-30 |
2022-08-10 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
CN113039208B
(zh)
*
|
2019-09-30 |
2022-11-04 |
和铂医药(上海)有限责任公司 |
一种抗pd-l1抗原结合蛋白及其应用
|
|
JP7495489B2
(ja)
*
|
2019-10-21 |
2024-06-04 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
|
|
EP4048315B1
(en)
|
2019-10-25 |
2025-03-12 |
Bolt Biotherapeutics, Inc. |
Thienoazepine immunoconjugates, and uses thereof
|
|
US20230044248A1
(en)
*
|
2019-11-01 |
2023-02-09 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
|
US20230340122A1
(en)
*
|
2019-11-05 |
2023-10-26 |
Glaxosmithkline Intellectual Property (No. 4) Ltd. |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
US12516133B2
(en)
|
2019-11-27 |
2026-01-06 |
Shanghai Epimab Biotherapeutics Co., Ltd |
TGFβ/PD-L1 bispecific binding proteins
|
|
CA3158047A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Yunying CHEN |
Bi-functional antibody against pd-l1 and tgf?
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
WO2021123432A1
(en)
|
2019-12-20 |
2021-06-24 |
Ares Trading S.A. |
Igg:tgfbetarii fusion protein composition
|
|
EP3838260A1
(en)
|
2019-12-20 |
2021-06-23 |
Ares Trading S.A. |
Igg:tgf rii fusion protein composition
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
JP7675083B2
(ja)
*
|
2020-01-09 |
2025-05-12 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規４－１ｂｂｌ三量体含有抗原結合分子
|
|
JP2023511363A
(ja)
*
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
JP2023511362A
(ja)
*
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
CN115135675A
(zh)
*
|
2020-02-18 |
2022-09-30 |
南京金斯瑞生物科技有限公司 |
融合蛋白及其用途
|
|
CN115175942B
(zh)
*
|
2020-02-25 |
2025-05-30 |
上海药明生物技术有限公司 |
一种双功能融合蛋白及其用途
|
|
WO2021185337A1
(zh)
|
2020-03-20 |
2021-09-23 |
荣昌生物制药(烟台)股份有限公司 |
一种双特异性融合蛋白及其应用
|
|
AU2021256925A1
(en)
*
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
|
KR20230003178A
(ko)
*
|
2020-04-29 |
2023-01-05 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
PD-1 및 TGF-β에 대한 이중 기능성 단백질
|
|
IL297782A
(en)
|
2020-05-01 |
2022-12-01 |
Bolt Biotherapeutics Inc |
Anti-dectin-2 antibodies
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
CA3183673A1
(en)
*
|
2020-06-26 |
2021-12-30 |
Robert Allen |
Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
|
|
US12194094B2
(en)
|
2020-07-10 |
2025-01-14 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
EP4194002A4
(en)
*
|
2020-07-24 |
2024-08-14 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
CN121319180A
(zh)
*
|
2020-07-28 |
2026-01-13 |
乐普生物科技股份有限公司 |
靶向PD-L1和TGF-β的双功能分子
|
|
TW202214287A
(zh)
*
|
2020-08-24 |
2022-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2023539645A
(ja)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｎｋｐ３０に結合する抗体分子およびその使用
|
|
WO2022042715A1
(zh)
*
|
2020-08-31 |
2022-03-03 |
杭州九源基因工程有限公司 |
靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
EP4165086A4
(en)
*
|
2020-09-16 |
2024-07-31 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022063114A1
(zh)
*
|
2020-09-23 |
2022-03-31 |
海正生物制药有限公司 |
Tgfbr2-ecd突变体及包含其的融合蛋白与应用
|
|
CN116323657B
(zh)
*
|
2020-09-24 |
2023-12-08 |
上海齐鲁制药研究中心有限公司 |
同时靶向PD-L1和TGFβ的双功能分子及其医药用途
|
|
CN114349867B
(zh)
*
|
2020-10-14 |
2024-05-28 |
广东菲鹏制药股份有限公司 |
融合蛋白及其应用
|
|
US20230372319A1
(en)
|
2020-11-02 |
2023-11-23 |
Ares Trading S.A. |
Combination Treatment of Cancer
|
|
WO2022090527A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN114573701A
(zh)
*
|
2020-12-02 |
2022-06-03 |
上海华奥泰生物药业股份有限公司 |
抗PD-L1/TGF-β双功能抗体及其用途
|
|
WO2022125891A2
(en)
|
2020-12-11 |
2022-06-16 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
JP2023552790A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
WO2022174451A1
(zh)
|
2021-02-22 |
2022-08-25 |
浙江道尔生物科技有限公司 |
一种具有抗癌活性的多结构域融合蛋白
|
|
CN114984203A
(zh)
*
|
2021-03-01 |
2022-09-02 |
正大天晴药业集团股份有限公司 |
包含靶向PD-L1和TGF-β的融合蛋白的药物组合物
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
CN114984204A
(zh)
*
|
2021-03-02 |
2022-09-02 |
正大天晴药业集团股份有限公司 |
治疗肿瘤的联用药物
|
|
CN117015394A
(zh)
*
|
2021-03-12 |
2023-11-07 |
博际生物医药科技(杭州)有限公司 |
结合人TGFβ和PD-L1的双功能分子及其应用
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
CN117769439A
(zh)
|
2021-03-26 |
2024-03-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
|
|
US20250281633A1
(en)
|
2021-05-03 |
2025-09-11 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
CN114773485B
(zh)
*
|
2021-05-11 |
2024-05-17 |
江苏先声药业有限公司 |
抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
|
|
US20240226319A1
(en)
|
2021-05-25 |
2024-07-11 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
EP4351640A1
(en)
|
2021-06-07 |
2024-04-17 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CA3230292A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
|
|
EP4469489A4
(en)
|
2022-01-28 |
2026-04-08 |
35Pharma Inc |
Type IIB Variants of the Activin Receptor and Their Uses
|
|
CN114990129B
(zh)
*
|
2022-05-11 |
2023-02-03 |
北京贝来生物科技有限公司 |
表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
|
|
US20250282874A1
(en)
|
2022-05-17 |
2025-09-11 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Bifunctional protein, and preparation thereof and use thereof
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
WO2024173387A1
(en)
|
2023-02-14 |
2024-08-22 |
Bolt Biotherapeutics, Inc. |
Aza-benzazepine immunoconjugates, and uses thereof
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
EP4694894A1
(en)
|
2023-04-12 |
2026-02-18 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024216089A1
(en)
|
2023-04-13 |
2024-10-17 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibody combination therapy
|
|
CN121729432A
(zh)
|
2023-06-23 |
2026-03-24 |
派克西斯肿瘤学公司 |
抗klrg1抗体及其用途
|
|
CN122094976A
(zh)
*
|
2023-10-31 |
2026-05-26 |
免疫生物公司 |
多链嵌合多肽和其用途
|
|
IL328577A
(en)
*
|
2023-11-24 |
2026-07-01 |
Medpacto Inc |
Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use
|
|
WO2025140212A1
(en)
*
|
2023-12-26 |
2025-07-03 |
Laekna Therapeutics Shanghai Co., Ltd. |
Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
|
|
US20260092096A1
(en)
|
2024-05-14 |
2026-04-02 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|